Literature DB >> 28292491

Joint Utility Estimators in Substance Use Disorders.

Eve Wittenberg1, Jeremy W Bray2, Achamyeleh Gebremariam3, Brandon Aden4, Bohdan Nosyk5, Bruce R Schackman4.   

Abstract

BACKGROUND: Although co-occurring conditions are common with substance use disorders (SUDs), estimation methods for joint health state utilities have not yet been tested in this context.
OBJECTIVES: To compare joint health state utility estimators in SUD to inform economic evaluation.
METHODS: We conducted two Internet-based surveys of US adults to collect community perspective standard gamble utilities for SUD and common co-occurring conditions. We evaluated six conditions as they occur individually and four combinations of these as they occur in tandem. We applied joint utility estimators using the six individual conditions' utilities to compare their performance relative to the observed combination states' utilities. We assessed performance with bias (estimated utility minus observed utility) and root mean square error (RMSE).
RESULTS: Using 3892 utilities from 1502 respondents, the minimum estimator was statistically unbiased (i.e., the 95% confidence interval included 0) for all combination states that we measured. The maximum estimator was unbiased for two states and the linear index and adjusted decrement estimators were unbiased for one state. The maximum estimator had the smallest RMSE for two combination states (back pain and prescription opioid misuse [0.0004] and injection crack and injection opioid use [0.0007]); the linear index and minimum estimators had the smallest RMSE for one combination state each. The additive and multiplicative estimators had the largest RMSE for all states.
CONCLUSIONS: Our results demonstrate the usefulness of the minimum estimator in this context, and confirm the inadequacy of the additive and multiplicative estimators. Further research is needed to extend these results to other SUD states.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost-utility analysis; preferences; substance use; utility

Mesh:

Year:  2016        PMID: 28292491      PMCID: PMC5356490          DOI: 10.1016/j.jval.2016.09.2404

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  15 in total

1.  Predicting utility for joint health states: a general framework and a new nonparametric estimator.

Authors:  Alex Z Fu
Journal:  Med Decis Making       Date:  2010-07-19       Impact factor: 2.583

2.  What is the best model for estimating joint health states utilities? Comparing the linear index model to the proportional decrement model.

Authors:  William Dale
Journal:  Med Decis Making       Date:  2010 Sep-Oct       Impact factor: 2.583

3.  A linear index for predicting joint health-states utilities from single health-states utilities.

Authors:  Anirban Basu; William Dale; Arthur Elstein; David Meltzer
Journal:  Health Econ       Date:  2009-04       Impact factor: 3.046

4.  Ordering errors, objections and invariance in utility survey responses: a framework for understanding who, why and what to do.

Authors:  Eve Wittenberg; Lisa A Prosser
Journal:  Appl Health Econ Health Policy       Date:  2011-07-01       Impact factor: 2.561

5.  Does mode of administration matter? Comparison of online and face-to-face administration of a time trade-off task.

Authors:  Richard Norman; Madeleine T King; Dushyant Clarke; Rosalie Viney; Paula Cronin; Deborah Street
Journal:  Qual Life Res       Date:  2010-02-22       Impact factor: 4.147

Review 6.  Health state descriptions. Purposes, issues, a proposal.

Authors:  H A Llewellyn-Thomas
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

7.  The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.

Authors:  William Dale; S Pinar Bilir; Joshua Hemmerich; Anirban Basu; Arthur Elstein; David Meltzer
Journal:  Med Care       Date:  2011-01       Impact factor: 2.983

Review 8.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

9.  Co-occurrence of leading lifestyle-related chronic conditions among adults in the United States, 2002-2009.

Authors:  Earl S Ford; Janet B Croft; Samuel F Posner; Richard A Goodman; Wayne H Giles
Journal:  Prev Chronic Dis       Date:  2013-04-25       Impact factor: 2.830

10.  Multiple chronic conditions among US adults: a 2012 update.

Authors:  Brian W Ward; Jeannine S Schiller; Richard A Goodman
Journal:  Prev Chronic Dis       Date:  2014-04-17       Impact factor: 2.830

View more
  7 in total

1.  Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.

Authors:  Zoe Ward; Nyashadzaishe Mafirakureva; Jack Stone; Mary Keevans; Graham Betts-Symonds; Desmond Crowley; Tina McHugh; Gordana Avramovic; John S Lambert; Peter Vickerman
Journal:  Int J Drug Policy       Date:  2021-08-17

2.  Health-related quality of life of alcohol use disorder with co-occurring conditions in the US population.

Authors:  Eve Wittenberg; Carolina Barbosa; Riley Hein; Emma Hudson; Benjamin Thornburg; Jeremy W Bray
Journal:  Drug Alcohol Depend       Date:  2021-01-29       Impact factor: 4.492

3.  SF-6D utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population.

Authors:  Carolina Barbosa; Jeremy W Bray; William N Dowd; Alan Barnosky; Eve Wittenberg
Journal:  Addiction       Date:  2020-08-27       Impact factor: 6.526

4.  Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.

Authors:  Sarah Gutkind; Bruce R Schackman; Jake R Morgan; Jared A Leff; Linda Agyemang; Sean M Murphy; Matthew J Akiyama; Brianna L Norton; Alain H Litwin; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 20.999

5.  Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.

Authors:  Joshua A Barocas; Jake R Morgan; David A Fiellin; Bruce R Schackman; Golnaz Eftekhari Yazdi; Michael D Stein; Kenneth A Freedberg; Benjamin P Linas
Journal:  Int J Drug Policy       Date:  2019-05-10

6.  Modeling the impact of COVID-19 pandemic-driven increases in alcohol consumption on health outcomes and hospitalization costs in the United States.

Authors:  Carolina Barbosa; William N Dowd; Simon J Neuwahl; Jürgen Rehm; Sameer Imtiaz; Gary A Zarkin
Journal:  Addiction       Date:  2022-08-01       Impact factor: 7.256

7.  Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.

Authors:  Bruce R Schackman; Sarah Gutkind; Jake R Morgan; Jared A Leff; Czarina N Behrends; Kevin L Delucchi; Courtney McKnight; David C Perlman; Carmen L Masson; Benjamin P Linas
Journal:  Drug Alcohol Depend       Date:  2018-02-21       Impact factor: 4.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.